Abstract:BACKGROUND & AIMS:Plasma ceramides have been identified as novel risk factors for metabolic and cardiovascular diseases. We aimed to evaluate the effects of dietary anthocyanins on plasma ceramides and to disentangle whether the alterations in ceramides could be related with those in other cardiometabolic risk factors in the dyslipidemia. METHODS:In a randomized double-blinded placebo-controlled trial, 176 eligible dyslipidemia subjects were randomly assigned into four groups receiving placebo, 40, 80, or 320 mg/day anthocyanins, respectively for 12 weeks. RESULTS:A total of 169 subjects completed the study. After 12-week intervention, dietary anthocyanins dose-dependently reduced plasma concentrations of all six ceramide species in the dyslipidemia subjects (all Ptrend values < 0.05). Specifically, 320 mg/day anthocyanins effectively lowered plasma N-palmitoylsphingosine (Cer 16:0, mean change: -28.3 ± 41.2 versus 2.9 ± 38.2, nmol/L, P = 0.018) and N-tetracosanoylsphingosine (Cer 24:0, mean change: -157.1 ± 493.9 versus 10.7 ± 439.9, nmol/L, P = 0.002) compared with the placebo. The declines in plasma Cer 16:0 and Cer 24:0 were significantly correlated with the decreases in plasma non-high-density lipoprotein cholesterol (nonHDL-C, Spearman's r = 0.32, P = 0.040 for Cer 16:0; Spearman's r = 0.35, P = 0.026 for Cer 24:0), apolipoprotein B (Spearman's r = 0.33, P = 0.031 for Cer 16:0; Spearman's r = 0.48, P = 0.002 for Cer 24:0), and total cholesterol (Spearman's r = 0.34, P = 0.026 for Cer 16:0; Spearman's r = 0.31, P = 0.042 for Cer 24:0) after 12-week 320 mg/day anthocyanin administration. Besides, we found that anthocyanins at 320 mg/day also markedly enhanced cholesterol efflux capacity in the dyslipidemia, the changes of which were positively associated with the reductions in Cer 16:0 (Spearman's r = 0.42, P = 0.006) independent of HDL-C and apolipoprotein A-I. CONCLUSIONS:Reductions in plasma Cer 16:0 and Cer 18:0 after 12-week anthocyanin intervention were dose-dependently associated with improvements in plasma lipids and cholesterol efflux capacity in the dyslipidemia. CLINICAL TRIAL REGISTRATION:The study was registered at ClinicalTrials.gov with the identifier No. NCT03415503.

Anthocyanin Prevents CD40-Activated Proinflammatory Signaling in Endothelial Cells by Regulating Cholesterol Distribution

Anthocyanin attenuates CD40-mediated endothelial cell activation and apoptosis by inhibiting CD40-induced MAPK activation.

Tanshinone II A Attenuates TNF-α-Induced Expression of VCAM-1 and ICAM-1 in Endothelial Progenitor Cells by Blocking Activation of NF-κB.

S‐Allyl‐L‐Cysteine Sulfoxide Inhibits Tumor Necrosis Factor‐Alpha Induced Monocyte Adhesion and Intercellular Cell Adhesion Molecule‐1 Expression in Human Umbilical Vein Endothelial Cells

Anti-inflammatory Effect of Purified Dietary Anthocyanin in Adults with Hypercholesterolemia: A Randomized Controlled Trial

Anthocyanins Induce Cholesterol Efflux from Mouse Peritoneal Macrophages: THE ROLE OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR γ-LIVER X RECEPTOR α-ABCA1 PATHWAY

Cyanidin-3-O-β-glucoside Induces Oxysterol Efflux from Endothelial Cells: Role of Liver X Receptor Alpha

Anthocyanin Attenuates Disturbance of Intestinal Barrier in High-Fat/high-cholesterol Diet-Challenged Mice Through Regulating the Response of T-helper 17 Cells

Cyanidin-3-O-β-glucoside inhibits iNOS and COX-2 expression by inducing liver X receptor alpha activation in THP-1 macrophages

Anthocyanins in Vascular Health and Disease: Mechanisms of Action and Therapeutic Potential

EFFECT OF ANTHOCYANINS ON INFLAMMATORY SIGNAL TRANSDUCTION IN ApoE KNOCK-OUT MICE

Bilberry-derived anthocyanins prevent IFN-γ-induced pro-inflammatory signalling and cytokine secretion in human THP-1 monocytic cells

EFFECTS OF ANTHOCYANIN ON LIPOPOLYSACCHARIDE-INDUCED INFLAMMATORY RESPONSE IN MACROPHAGES

[The Effect of Anthocyanins on Cholesterol Efflux from Mouse Peritoneal Macrophage-Derived Foam Cells and Its Possible Molecular Mechanism].

Purified anthocyanin supplementation improves endothelial function via NO-cGMP activation in hypercholesterolemic individuals.

Structural requirements of anthocyanins in relation to inhibition of endothelial injury induced by oxidized low-density lipoprotein and correlation with radical scavenging activity.

Cyanidin-3-O-β-glucoside with the Aid of Its Metabolite Protocatechuic Acid, Reduces Monocyte Infiltration in Apolipoprotein E-deficient Mice.

Anthocyanin Supplementation Improves Serum LDL- and HDL-cholesterol Concentrations Associated with the Inhibition of Cholesteryl Ester Transfer Protein in Dyslipidemic Subjects.

Natural Compound Resveratrol Attenuates TNF-Alpha-Induced Vascular Dysfunction in Mice and Human Endothelial Cells: The Involvement of the NF-κB Signaling Pathway

Dose-dependent reductions in plasma ceramides after anthocyanin supplementation are associated with improvements in plasma lipids and cholesterol efflux capacity in dyslipidemia: A randomized controlled trial.

Anthocyanin Supplementation Improves Anti-Oxidative and Anti-Inflammatory Capacity in a Dose–response Manner in Subjects with Dyslipidemia